List of health departments and ministries

Cannabis Industry Leaders Call for Immediate Government Intervention to Prevent Systemic Failure of Small Businesses and Craft Farms

Retrieved on: 
Vendredi, octobre 28, 2022
ISED, Deloitte, Commerce, C3, VP, Growth, Government, CEO, Risk, Environment, List of health departments and ministries, Income, Small business, CCAA, Association, Finance minister, Economic development, Industry, Compliance, International, Canada Revenue Agency, Innovation, Science and Economic Development Canada, Ernst, Farm, Cannabis, Canadian Chamber of Commerce in Shanghai, CRA, Drug, Renewable energy, Science, Policy

Vancouver, British Columbia--(Newsfile Corp. - October 28, 2022) - Today StandforCraft.com, in association with the Cannabis Council of Canada and the Canadian Chamber of Commerce, published their latest in a series of working papers demonstrating the need for immediate intervention in excise tax policy for Canadian cannabis.

Key Points: 
  • StandForCraft.com , Cannabis Council of Canada, and Canadian Chamber of Commerce unite to endorse a short form working paper demonstrating the immediate need for intervention to save failing small businesses in Canadian cannabis .
  • The paper demonstrates a systemic lack of breakeven income levels for firms large and small across the sector.
  • "The time for intervention has come and gone, and without immediate action the participation of small businesses in the future of legal Canadian cannabis is materially at risk," Sutton added.
  • The Cannabis Council of Canada ('C3') is the national and international representative of Canada's licensed producers and processors of cannabis.

Tel Aviv Listed Together Pharma’s Subsidiary Globus Pharma Ltd and BYND Cannasoft Enterprises’ Subsidiary Sign First Commercial Agreement for Medical Cannabis Products

Retrieved on: 
Jeudi, octobre 27, 2022
Ministry, CRM, Company, BETA, NASDAQ, MCU, Human, Software, CEO, SEDAR, List of health departments and ministries, Income, BCAN, CSE, TA, Patient, BYND, Industry, Pharmacy, Research, GLOBE, Marketing, Cannabis, Sale, Pharmaceutical industry, Drug

The manufacturing of the medical cannabis products will adhere to BYND Cannasoft's instructions and stringent standards.

Key Points: 
  • The manufacturing of the medical cannabis products will adhere to BYND Cannasoft's instructions and stringent standards.
  • These products will be exclusively marketed and distributed by BYND Cannasoft in Israel through Globus Pharma.
  • Due to their safety profile and strong therapeutic efficacy, the products are based on strains developed by Together Pharma and selected exclusively by BYND Cannasoft.
  • Israel has emerged as one of the leading countries for the consumption of medical cannabis in the world.

BYND Cannasoft Enterprises CEO Discusses Marijuana Reform and Corporate Advancements in Audio Interview with SmallCapVoice.com

Retrieved on: 
Mardi, octobre 25, 2022
News, Weizmann Institute of Science, Human, Weizmann, Sale, White House, CRM, Pharmacy, Science, Solution, List of health departments and ministries, Cannabis, White, Research, Investment, Nasdaq, R, Software, Company, Marketing, BETA, Industry, Acquisition, SCV, CSE, CEO, BCAN, Patent, Interview, GLOBE, Ministry, BYND, Â, SEDAR, Drug, Pharmaceutical industry, Retail, Property management, CBD, Health

Though based in Israel, Ben Yaackov acknowledges that BYND is poised to benefit from marijuana policy reform in the United States.

Key Points: 
  • Though based in Israel, Ben Yaackov acknowledges that BYND is poised to benefit from marijuana policy reform in the United States.
  • In line with this strategy, the Medical Cannabis Unit at Israel's Ministry of Health recently granted BYND an initial approval to engage in medical cannabis.
  • BYND doesnt shy away from investments, but it does maintain a strategic approach that enables it to grow specific areas of focus.
  • To view the full interview with SCV, visit: https://youtu.be/Bkw3zrvUw78
    About BYND Cannasoft Enterprises Inc.
    BYND is an integrated software/cannabis company based in Israel.

Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research

Retrieved on: 
Vendredi, octobre 7, 2022
Quality of life, Merck, List of health departments and ministries, Sale, Kerala State Drugs and Pharmaceuticals Limited, Patient, Dostarlimab, BIS, GlaxoSmithKline, Pembrolizumab, Colorectal cancer, BTC, Report, Center for Urban and Regional Analysis, TRADD, PD-1, Research, Adult, Patent, FREE, Ministry, Cisplatin, CD80, Name, Bristol Myers Squibb, Medical device, Pharmaceutical industry, Palladium, Health

FREMONT, Calif., Oct. 7, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled  PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis. 

Key Points: 
  • More and more research activities are taking place in order to maximize the therapeutic potential of PD-1/PDL-1 inhibitors and great results have been demonstrated as well."
  • In September 2022, Merck's anti-PD-1 therapy KEYTRUDA received four new approvals from Japan's Ministry of Health, Labor and Welfare.
  • Keytruda is also the first product approved under the PD-1/PDL-1 inhibitor category of immune checkpoint inhibitors and has a patent valid till 2028.
  • BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscape.

Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research

Retrieved on: 
Vendredi, octobre 7, 2022
Quality of life, Merck, List of health departments and ministries, Sale, Kerala State Drugs and Pharmaceuticals Limited, Patient, Dostarlimab, BIS, GlaxoSmithKline, Pembrolizumab, Colorectal cancer, BTC, Report, Center for Urban and Regional Analysis, TRADD, PD-1, Research, Adult, Patent, FREE, Ministry, Cisplatin, CD80, Name, Bristol Myers Squibb, Medical device, Pharmaceutical industry, Palladium, Health

FREMONT, Calif., Oct. 7, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled  PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis. 

Key Points: 
  • More and more research activities are taking place in order to maximize the therapeutic potential of PD-1/PDL-1 inhibitors and great results have been demonstrated as well."
  • In September 2022, Merck's anti-PD-1 therapy KEYTRUDA received four new approvals from Japan's Ministry of Health, Labor and Welfare.
  • Keytruda is also the first product approved under the PD-1/PDL-1 inhibitor category of immune checkpoint inhibitors and has a patent valid till 2028.
  • BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscape.

GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders

Retrieved on: 
Vendredi, octobre 7, 2022
U.S. Securities and Exchange Commission, Uncertainty, Securities Act of 1933, Therapy, Risk, Schizophrenia, ASD, Family, Annual report, Securities Exchange Act of 1934, Patient, Twitter, Security (finance), Private Securities Litigation Reform Act, Lists of diseases, List of health departments and ministries, Company, Industry, Alzheimer's disease, Nature, Autism, Safety, OTC, GLOBE, Clinical trial, Solution, Pharmaceutical industry, Health

The Company intends to conduct a Phase 2 clinical trial spearheaded by principal investigator, Dr. Adi Aran, to study the safety and efficacy of its neuroprotective cannabinoid therapeutic to treat autism related spectrum disorders (ASD) and other neuropsychiatric illnesses.

Key Points: 
  • The Company intends to conduct a Phase 2 clinical trial spearheaded by principal investigator, Dr. Adi Aran, to study the safety and efficacy of its neuroprotective cannabinoid therapeutic to treat autism related spectrum disorders (ASD) and other neuropsychiatric illnesses.
  • The study will be conducted as a double-blind, placebo controlled trial with 100 patients ranging in age from 4-17 years old.
  • We are excited to take this next step in the advancement of our novel therapeutic to clinical trials, said Aitan Zacharin, Chief Executive Officer of GCANRx.
  • To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

Fourth Generation CathWorks FFRangio® System Receives Regulatory Approval in Japan

Retrieved on: 
Jeudi, octobre 6, 2022
Physician, LinkedIn, Disease, Cardiovascular disease, Diagnosis, List of health departments and ministries, CAD, MHLW, Patient, Intelligence, Twitter, Medtronic, Partnership, Veni, vidi, vici, Automation, Nasiriyah Heart Center, Ministry of Health, Labour and Welfare, Department, CEO, Medicines and Healthcare products Regulatory Agency, Coronary artery disease, Ministry, PMDA, Pharmaceutical industry, Medical device, Health

KFAR-SABA, Israel and IRVINE, Calif., Oct. 6, 2022 /PRNewswire/ -- CathWorks announced today the approval of the fourth generation CathWorks FFRangio System by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

Key Points: 
  • KFAR-SABA, Israel and IRVINE, Calif., Oct. 6, 2022 /PRNewswire/ -- CathWorks announced today the approval of the fourth generation CathWorks FFRangio System by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
  • The CathWorks FFRangio System has been the first non-invasive device of its kind to receive Japan PMDA and Ministry of Health, Labour and Welfare (MHLW) approval for diagnosis of functional ischemia for patients with ischemic CAD.
  • The fourth-generation application includes significant automation and enhancements, while offering the same exceptional 93% diagnostic accuracy when compared to invasive wire-derived FFR.1
    "The PMDA approval of the fourth generation CathWorks FFRangio System is another significant milestone for CathWorks, physicians and patients," said Ramin Mousavi, President and CEO of CathWorks.
  • The CathWorks FFRangio System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated.

Global Typhoid Fever Vaccines Market Report 2022: Increasing Government & NGO Initiatives to Raise Awareness Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Mardi, octobre 4, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, People, Vaccine, Ministry, Route of administration, Water, Typhoid fever, Immunity, Industry, List of health departments and ministries, WHO, CAGR, Drinking water, TCV, Time-invariant system, Region, Subclinical infection, Constipation, Headache, Croydon typhoid outbreak of 1937, Fever, Gavi, Partnership, Genetically modified bacteria, Salmonella, US, Mouth, Centers for Disease Control and Prevention, Center, Administration, Nausea, Organization, Marketing, Salmonella enterica subsp. enterica, Symptoms of COVID-19, Awareness

The "Typhoid Fever Vaccines Market, by Vaccine Type, by Route of Administration, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Typhoid Fever Vaccines Market, by Vaccine Type, by Route of Administration, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea.
  • Typhoid fever vaccines are the biological formulations, which provide immunity and protect an individual against typhoid fever.
  • Increasing initiatives by governments and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to drive the typhoid fever vaccines market growth during forecast period.

An Industry Leader and a New VP Join Kando's Journey to Make a Positive Impact on the UK Wastewater Scene

Retrieved on: 
Jeudi, septembre 15, 2022
VP, Digital, Carbon, Drinking water, Algorithm, COVID-19, Human, Ministry, Scottish Government, JBC, Compliance, Security agency, Partnership, Industry, Government, High-functioning autism, Intelligence, Water, Professional, Public health, List of health departments and ministries, Anomaly, Map, Degenerative disease, Scottish Water, UK Health Security Agency, Wastewater, IOT, Innovation, Joint Biosecurity Centre, Renewable energy, Sewage, Recycling, Service, Health

TSUR YIGAL, Israel, Sept. 15, 2022 /PRNewswire/ -- Kando, a data intelligence solution provider specializing in wastewater analysis, today announced a new partnership with a water utility in the UK. Scottish Water has joined forces with Kando to implement its wastewater intelligence solution and bolster its ability to harness wastewater for the benefit of community and public health. Kando is also announcing that Dr. Andrew Engeli has joined the company as VP Community Health Strategy and Services to facilitate the company's growing outreach efforts.

Key Points: 
  • Scottish Water has joined forces with Kando to implement its wastewater intelligence solution and bolster its ability to harness wastewater for the benefit of community and public health.
  • The UK government increasingly sees wastewater treatment as a priority area.
  • "I am very excited to be working together," said Dr. Andrew Engeli, VP Community Health Strategy and Services for Kando.
  • Scottish Water responded to this target by committing to net zero emissions by 2040, a full five years earlier.

An Industry Leader and a New VP Join Kando's Journey to Make a Positive Impact on the UK Wastewater Scene

Retrieved on: 
Jeudi, septembre 15, 2022
VP, Digital, Carbon, Drinking water, Algorithm, COVID-19, Human, Ministry, Scottish Government, JBC, Compliance, Security agency, Partnership, Industry, Government, High-functioning autism, Intelligence, Water, Professional, Public health, List of health departments and ministries, Anomaly, Map, Degenerative disease, Scottish Water, UK Health Security Agency, Wastewater, IOT, Innovation, Joint Biosecurity Centre, Renewable energy, Sewage, Recycling, Service, Health

TSUR YIGAL, Israel, Sept. 15, 2022 /PRNewswire/ -- Kando, a data intelligence solution provider specializing in wastewater analysis, today announced a new partnership with a water utility in the UK. Scottish Water has joined forces with Kando to implement its wastewater intelligence solution and bolster its ability to harness wastewater for the benefit of community and public health. Kando is also announcing that Dr. Andrew Engeli has joined the company as VP Community Health Strategy and Services to facilitate the company's growing outreach efforts.

Key Points: 
  • Scottish Water has joined forces with Kando to implement its wastewater intelligence solution and bolster its ability to harness wastewater for the benefit of community and public health.
  • The UK government increasingly sees wastewater treatment as a priority area.
  • "I am very excited to be working together," said Dr. Andrew Engeli, VP Community Health Strategy and Services for Kando.
  • Scottish Water responded to this target by committing to net zero emissions by 2040, a full five years earlier.